Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients With Coronavirus Disease 2019 (COVID-19)

Clin Infect Dis. 2022 Mar 1;74(4):752-753. doi: 10.1093/cid/ciab522.

Authors

Jeffrey D Jenks¹, Saima Aslam¹, Lucy E Horton¹, Nancy Law¹, Ajay Bharti¹, Cathy Logan¹, Mahnaz Taremi¹, Florin Vaida², Michele Ritter¹; COVID-19 Clinic Team

Collaborators

COVID-19 Clinic Team:
Ajay Bharti, Nancy Law, Kathleen Bordeaux, Claudia Guerrero, Diana Paddock, Joseph Bautista, Claudia Medrano, Sarah Arend, Mackenzie Williams, Marvin Ochoa Vega, Charisse Montilla

Affiliations

¹ Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
² Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, California, USA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use
COVID-19*
Hospitalization
Humans
Outpatients
SARS-CoV-2

Substances

Antibodies, Monoclonal